# Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

> **NCT01502410** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Childhood Hepatocellular Carcinoma
- Papillary Thyroid Cancer
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Liver Cancer
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Thyroid Cancer
- Recurrent Wilms Tumor and Other Childhood Kidney Tumors

## Interventions

- **DRUG:** sorafenib tosylate
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01502410
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502410, "Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01502410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*